LOG IN
SIGN UP
MARKET
IONS
IONS
Ionis Pharmaceuticals
NASDAQ
Real-time Quotes | Nasdaq Last Sale
36.65
-0.21
-0.57%
After Hours: 35.97 -0.68 -1.86% 16:04 05/26 EDT
OPEN
37.17
PREV CLOSE
36.86
HIGH
37.85
LOW
36.56
VOLUME
1.62M
TURNOVER
0
52 WEEK HIGH
44.42
52 WEEK LOW
25.04
MARKET CAP
5.20B
P/E (TTM)
-1327.8986
1D
5D
1M
3M
1Y
5Y
Ionis Pharmaceuticals' Angelman Syndrome therapy granted orphan drug status
The U.S. FDA has granted orphan drug status to an Ionis Pharmaceuticals (NASDAQ:IONS) antisense oligonucleotide candidate for Angelman Syndrome. The candidate, ION582, is partnered with Biogen (BIIB). In 2021, Ionis (IONS)
Seekingalpha · 10h ago
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.
Benzinga · 6d ago
Ionis to present at RBC Capital Markets Global Healthcare Conference
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.
PR Newswire · 05/12 11:05
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Benzinga · 05/09 20:32
--Morgan Stanley Trims Ionis Pharmaceuticals Price Target to $30 From $31, Underweight Rating Kept
MT Newswires · 05/09 12:16
We Think Ionis Pharmaceuticals (NASDAQ:IONS) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 05/06 11:23
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Zacks · 05/05 15:45
Recap: Ionis Pharmaceuticals Q1 Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:52
No Data
Learn about the latest financial forecast of IONS. Analyze the recent business situations of Ionis Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 22 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
13.64%Strong Buy
36.36%Buy
27.27%Hold
13.64%Under-perform
9.09%Sell
Analyst Price Target
The average IONS stock price target is 47.39 with a high estimate of 92.00 and a low estimate of 22.00.
Current 36.65
EPS
Actual
Estimate
-0.220.280.771.27
Institutional Holdings
Institutions: 515
Institutional Holdings: 138.80M
% Owned: 97.89%
Shares Outstanding: 141.80M
TypeInstitutionsShares
Increased
104
6.94M
New
45
3.65M
Decreased
105
6.43M
Sold Out
49
2.21M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Loscalzo
Chief Executive Officer/Director
Brett Monia
Chief Financial Officer/Executive Vice President - Finance
Elizabeth Hougen
Executive Vice President/Chief Scientific Officer
C. Frank Bennett
Executive Vice President
Joseph Baroldi
Executive Vice President
Onaiza Cadoret - Manier
Executive Vice President
Richard Geary
Executive Vice President
Eugene Schneider
Executive Vice President
Eric Swayze
General Counsel/Secretary
Patrick O'Neil
Other/Director
B. Lynne Parshall
Lead Director/Independent Director
Joseph Wender
Independent Director
Spencer Berthelsen
Independent Director
Allene Diaz
Independent Director
Michael Hayden
Independent Director
Joan Herman
Independent Director
Joseph Klein
Independent Director
Frederick Muto
No Data
No Data
About IONS
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).
Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.